Oral GLP-1 drugs are likely to expand the market massively The more disruptive development may actually be oral agents. Many patients are willing to take a pill but reluctant to self-inject indefinitely. Foundayo (orforglipron) – Lilly This is currently the most important oral competitor. Advantages: True oral GLP-1 No fasting requirement No water restrictions No injection training Lower manufacturing complexity than injectable peptides It received US approval for obesity in

Eli Lilly licensed global rights, excluding South Korea, to Hanmi Pharm's investigational long-acting GLP-2 analogue sonefpeglutide across multiple indications, under a deal potentially worth around $1.2 billion. The therapy, which is currently in Phase II development for the treatment of short bowel syndrome (SBS)-associated intestinal failure, employs Hanmi's LAPSCOVERY platform technology, enabling once-monthly subcutaneous administration. Hanmi will continue to conduct

Novo Nordisk launches multi-month subscriptions for Wegovy obesity drugs as it tries to catch up with Eli Lilly PUBLISHED TUE, MAR 31 20267:39 AM EDTUPDATED TUE, MAR 31 20262:10 PM EDT Annika Kim Constantino @ANNIKAKIMC SHARE Share Article via FacebookShare Article via TwitterShare Article via LinkedInShare Article via Email KEY POINTS Novo Nordisk launched a multi-month subscription program for its Wegovy obesity drug products that aims to ensure cash-paying patients pay low

https://mol.im/a/14668147